Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

WSC 2023 | FRONTIER: pre-hospital administration of nerinetide for acute ischemic stroke

Michael D. Hill, MD, University of Calgary, Alberta, Canada, speaks on results from the FRONTIER (NCT02315443) trial, run alongside ESCAPE-NEXT (NCT04462536), which assessed the efficacy of nerinetide in improving acute ischemic stroke outcomes when administered in a pre-hospital setting. Nerinetide is a neuroprotective molecule that interacts with postsynaptic density protein 95 (PSD-95) to alleviate neuronal damage during stroke. Patients with suspected ischemic stroke were administered nerinetide or control in the ambulance, before receiving routine reperfusion treatment at the hospital. Nerinetide was assessed as having a large treatment effect when administered within 60 minutes of symptom onset. Importantly, patients who did not go on to receive an ischemic stroke diagnosis had no effect of taking nerinetide, establishing a negative control. These findings are being used to inform a future trial which will assess the benefit of nerinetide, if given within a 3-hour time window, on the outcome of reperfusion therapy in acute ischemic stroke patients. This interview took place at the World Stroke Congress (WSC) 2023 in Toronto, Canada.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.


The ESCAPE-NEXT trial was funded by grants to the University of Calgary from the Canadian Institute for Health Research and from NoNO Inc.